

FREE* 60-DAY TRIAL

*Limitations and restrictions apply.

Actor portrayal

AMPYRA[®] (dalfampridine) Extended Release Tablets, 10 mg, is the first and only brand prescription medicine indicated to help improve walking in adults with multiple sclerosis (MS). This was demonstrated by an increase in walking speed.

Do not take AMPYRA if you have ever had a seizure, have certain types of kidney problems, or are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Please see Important Safety Information on page 3.



FREE* trial eligibility requirements:

- Your healthcare provider must determine that you are an appropriate candidate for AMPYRA[®] (dalfampridine).
- Patients participating in Medicare, Medicaid, or any other government-funded program are not eligible.
- Patients who have received a prescription for AMPYRA within the last 12 months are not eligible.

AMPYRAFreeTrial.com

Healthcare Provider

Please go to **AMPYRAFirstStepProgram.com** to get more information on the FREE* 60-day trial of AMPYRA and to download the form to enroll your eligible patient in this FREE* trial.

*Limitations and restrictions apply.

AMPYRA does not work for everyone, and people experience different levels of response to the medication. Ask your doctor if AMPYRA may be right for you.

Important Safety Information

Do not take AMPYRA if you:

- have ever had a seizure,
- · have certain types of kidney problems, or
- are allergic to dalfampridine (4-aminopyridine), the active ingredient in AMPYRA.

Take AMPYRA exactly as prescribed by your doctor.

Before taking AMPYRA, tell your doctor if you:

- have any other medical conditions
- are taking compounded 4-aminopyridine
- are taking any other prescription or OTC medicines, such as cimetidine
- are pregnant or plan to become pregnant. It is not known if AMPYRA will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if AMPYRA passes into your breast milk. You and your doctor should decide if you will take AMPYRA or breast-feed. You should not do both.

Stop taking AMPYRA and call your doctor right away if you have a seizure while taking AMPYRA. You could have a seizure even if you never had a seizure before. Your chance of having a seizure is higher if you take too much AMPYRA or if your kidneys have a mild decrease of function, which is common after age 50. Your doctor may do a blood test to check how well your kidneys are working before you start AMPYRA.

AMPYRA should not be taken with other forms of 4-aminopyridine (4-AP, fampridine), since the active ingredient is the same.

AMPYRA may cause dizziness or vertigo. If you have these symptoms do not drive,operate machinery or do other dangerous activities.

AMPYRA may cause serious side effects, including severe allergic reactions. Stop taking AMPYRA and call your doctor right away or get emergency medical help if you have shortness of breath or trouble breathing, swelling of your throat or tongue, or hives.

The most common side effects for AMPYRA in MS patients were urinary tract infection; trouble sleeping; dizziness; headache; nausea; weakness; back pain; problems with balance; multiple sclerosis relapse; burning, tingling, or itching of your skin; irritation in your nose and throat; constipation; indigestion; and pain in your throat.

Please see the Patient Medication Guide by visiting https://ampyra.com/medication-guide.pdf

Connect to AMPYRA[®] (dalfampridine) coverage

AMPYRA PATIENT SUPPORT SERVICES

AMPYRA Patient Support Services (APSS) helps make getting AMPYRA as simple as possible for eligible patients.

If you are prescribed AMPYRA, we offer assistance with insurance coverage and help with out-of-pocket costs, if you qualify.

We're also here to direct you to the right resources to help you get answers to questions you may have about AMPYRA.

HAVE QUESTIONS FOR APSS?

visit ampyra.com/support

OR CALL 1-888-881-1918 Monday through Friday from 8 AM to 8 PM ET



AMPYRA, ACORDA THERAPEUTICS, the stylized formatives of the foregoing, and the stylized pathway logo are trademarks of Acorda Therapeutics, Inc.

AMPYRA is marketed by Acorda Therapeutics, Inc. and manufactured under license from Alkermes Pharma Ireland Limited (APIL), Ireland. © 2022 Acorda Therapeutics, Inc. All rights reserved. 05/22 AMP11687

